The Team run by Didier Letourneur, CNRS Research Director and Director of Inserm U1148, located in Paris and awarded the George Winter Prize from the European Biomaterials Society, has developed a natural biocompatible hydrogel which is biodegradable
of variable and controlled pore size, and which can be produced in different forms (microbeads, dressings, etc.). This biomaterial is protected by several patent applications and offers the ability to develop numerous human health applications, such as those already demonstrated in animals for bone reconstitution and delivery of cells and molecules. In 2016 Inserm Transfert granted an Exclusive Marketing Licence to the SILTISS Company for this technology with the aim of developing medical devices for several applications in regenerative medicine. SILTISS is a subsidiary of the SILAB group and now has the financial and operational power of its parent company, which provides it with premises, clean rooms and a wide range of expertise, particularly that of its R&D teams.